University of Kansas Medical Center
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1906-01-01
- Employees
- 5K
- Market Cap
- -
- Website
- https://www.kumc.edu
Clinical Trials
450
Trial Phases
6 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (364 trials with phase data)• Click on a phase to view related trials
Connecting People With Cancer to Employment Support
- Conditions
- Cancer
- First Posted Date
- 2025-06-18
- Last Posted Date
- 2025-06-18
- Lead Sponsor
- University of Kansas Medical Center
- Target Recruit Count
- 70
- Registration Number
- NCT07027449
NLit and Outcomes in HNC Survivor-Caregiver Dyads
- Conditions
- Caregiver BurdenHealth Knowledge, Attitudes, PracticeHead and Neck Cancer
- First Posted Date
- 2025-06-15
- Last Posted Date
- 2025-06-15
- Lead Sponsor
- University of Kansas Medical Center
- Target Recruit Count
- 150
- Registration Number
- NCT07021885
- Locations
- 🇺🇸
University of Kansas Medical Center, Kansas City, Kansas, United States
Partial Sleep Restriction in Chronic Low Back Pain: A Feasibility Study
- Conditions
- Chronic Low-back PainInsomniaSleep
- First Posted Date
- 2025-06-06
- Last Posted Date
- 2025-06-06
- Lead Sponsor
- University of Kansas Medical Center
- Target Recruit Count
- 50
- Registration Number
- NCT07008924
- Locations
- 🇺🇸
University of Kansas Medical Center, Kansas City, Kansas, United States
Prospective Randomized Observer Blinded Single Center Study Comparing 90-day Functional Outcome in Patients Who Received Intravenous Propofol Infusion Versus Inhalational Sevoflurane for General Anesthesia During Mechanical Thrombectomy in Patients Who Suffered From Acute Ischemic Stroke
- Conditions
- Acute Ischemic Stroke Patients
- First Posted Date
- 2025-06-03
- Last Posted Date
- 2025-06-03
- Lead Sponsor
- University of Kansas Medical Center
- Target Recruit Count
- 120
- Registration Number
- NCT07001267
The Feasibility of LVHIIT on Inpatient Stroke Rehab
- Conditions
- StrokeHigh Intensity Interval TrainingAerobic FitnessPhysical Therapy
- First Posted Date
- 2025-05-31
- Last Posted Date
- 2025-05-31
- Lead Sponsor
- University of Kansas Medical Center
- Target Recruit Count
- 15
- Registration Number
- NCT06998017
- Prev
- 1
- 2
- 3
- 4
- 5
- 90
- Next
News
KU Medical Center Receives $31 Million NIH Grant to Expand Pediatric Clinical Trial Access in Underserved Areas
The University of Kansas Medical Center received a five-year, $31 million NIH grant to coordinate pediatric clinical trials across 18 rural and underserved sites, marking the largest award in the institution's history.
Springbok Analytics Pioneers AI-Driven MRI Analysis in Landmark Pediatric FSHD Study
The NIH-funded MOVE Peds study represents the first large-scale clinical investigation of pediatric facioscapulohumeral muscular dystrophy (FSHD), addressing critical gaps in understanding disease progression in children.
NOURISH Trial Addresses Food Insecurity and Malnutrition in Blood Cancer Patients During Treatment
• A groundbreaking clinical trial, NOURISH, aims to combat food insecurity and malnutrition in blood cancer patients undergoing transplant or cellular therapy through structured food assistance programs. • Cancer patients experiencing malnutrition face increased risks of infection, longer hospital stays, reduced treatment tolerance, and higher mortality rates, according to Dr. Anna Arthur, the study's primary investigator. • The trial provides patients with bi-weekly food bags containing 2-3 days of balanced nutrition, along with recipes and cooking demonstrations to support optimal nutritional intake during treatment.
CAR-T Therapy Shows Promise in Earlier Treatment Lines for Relapsed/Refractory Multiple Myeloma
• Two leading CAR-T cell therapies, ciltacabtagene autoleucel and idecabtagene vicleucel, demonstrate encouraging results in treating relapsed/refractory multiple myeloma patients in earlier treatment lines. • Clinical data supports the potential benefits of moving CAR-T cell therapy to earlier treatment stages, potentially improving patient outcomes before disease progression becomes more advanced. • Healthcare institutions are developing structured referral processes and treatment protocols to optimize patient selection and timing of CAR-T therapy implementation.